Overview

Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction - Coronary Computed Tomography Angiography Trial

Status:
NOT_YET_RECRUITING

Trial end date:
2028-06-02

Target enrollment:

Participant gender:

Summary

The primary objective of this trial is to evaluate the effect of olpasiran, compared to placebo, on non-calcified plaque (NCP) volume as measured by Coronary Computed Tomography Angiography (CCTA).

Phase:

PHASE3

Details

Lead Sponsor:

Amgen

Treatments:

olpasiran